Early Patterns of Gene Expression Correlate With the Humoral Immune Response to Influenza Vaccination in Humans

Department of Pathology & Immunology, Baylor College of Medicine, Houston, Texas 77030-2504, USA.
The Journal of Infectious Diseases (Impact Factor: 5.78). 02/2011; 203(7):921-9. DOI: 10.1093/infdis/jiq156
Source: PubMed

ABSTRACT Annual vaccination is the primary means for preventing influenza. However, great interindividual variability exists in vaccine responses, the cellular events that take place in vivo after vaccination are poorly understood, and appropriate biomarkers for vaccine responsiveness have not been developed.
We immunized a cohort of healthy male adults with a licensed trivalent influenza vaccine and performed a timed assessment of global gene expression before and after vaccination. We analyzed the relationship between gene expression patterns and the humoral immune response to vaccination.
Marked up regulation of expression of genes involved in interferon signaling, positive IL-6 regulation, and antigen processing and presentation, were detected within 24 hours of immunization. The late vaccine response showed a transcriptional pattern suggestive of increased protein biosynthesis and cellular proliferation. Integrative analyses revealed a 494-gene expression signature--including STAT1, CD74, and E2F2--which strongly correlates with the magnitude of the antibody response. High vaccine responder status correlates with increased early expression of interferon signaling and antigen processing and presentation genes.
The results highlight the role of a systems biology approach in understanding the molecular events that take place in vivo after influenza vaccination and in the development of better predictors of vaccine responsiveness.

Download full-text


Available from: Molly Bray, Jul 29, 2015
  • Source
    • "We and others have shown that for some transcripts there is significant correlation between the magnitude of the transcriptional and antibody responses to the vaccine stimulus (Zhu et al., 2010; Bucasas et al., 2011; Nakaya et al., 2011) In a combined analysis of the two cohorts in the present study, 301 transcripts were found to correlate with the magnitude of the antibody response (Figure 4). Additional details of these 301 transcripts, including correlation coefficients and days of maximum correlation, are provided in Table 3 via the Interactive Results Tool (which is also available to download from Zenodo and shown within Supplementary file 1). "
    [Show abstract] [Hide abstract]
    ABSTRACT: eLife digest Vaccines increase resistance to disease by priming the immune system to respond to specific viruses or microorganisms. By presenting a weakened (or dead) form of a pathogen, or its toxins or surface proteins, to the immune system, vaccines trigger the production of antibodies against the virus or microorganism. If a vaccinated individual then encounters the pathogen, their immune system should be able to recognize and destroy it. Many vaccines also include a secondary agent, known as an adjuvant, to further stimulate the immune response. Influenza, an RNA virus commonly referred to as the ‘flu’, is an infectious disease that affects both birds and mammals. Seasonal epidemics occur each year affecting 2–7% of the population. According to the World Health Organization, influenza leads to nearly 5 million hospitalizations each year and causes up to half a million deaths. Vaccination is a primary strategy for the prevention of seasonal influenza, but responses to the vaccine vary markedly, partly because of variation in the genetic makeup or genotype of individuals. However, the details of how genes influence response to vaccination, and indeed susceptibility to influenza, remain unclear. To investigate the genetic basis of variation in the immune response of healthy adults to the seasonal influenza vaccine, Franco et al. combined information about the genotypes of individuals with measurements of their gene transcription and antibody response to vaccination. They identified 20 genes that contributed to differential immune responses to the vaccine. Almost half of these encode proteins that are not specifically associated with the immune system, but have more general roles in processes such as membrane trafficking and intracellular transport. Focusing on these genes may enable researchers to spot those individuals who are less likely to respond to a vaccine. It could also open up new avenues of research for vaccine development: rather than designing adjuvants that target known immune mechanisms, researchers should develop adjuvants that target the proteins encoded by these 20 genes. DOI:
    eLife Sciences 07/2013; 2:e00299. DOI:10.7554/eLife.00299 · 8.52 Impact Factor
  • Source
    • "Additional 'metagenes' associated with aging (Hong et al. 2008) and other clinical endpoints based on published as well as proprietary data sets were constructed to enrich our capacity for data interpretation and hypothesis generation in several infectious disease and vaccine preclinical and clinical studies. Most of the reported vaccine-related blood profiling studies focused on identifying genes which predict vaccine efficacy (Bucasas et al. 2011; Gaucher et al. 2008; Nakaya et al. 2011; Palermo et al. 2011; Querec et al. 2009; Vahey et al. 2010). Expression levels of two genes, eukaryotic translation initiation factor 2 a kinase 4 (EIF2AK4) and solute carrier family 2, member 6 (SLC2A6) were associated with antibody titers and antigen-specific CD8 ? "
    [Show abstract] [Hide abstract]
    ABSTRACT: The pharmaceutical industry is spending increasingly large amounts of money on the discovery and development of novel medicines, but this investment is not adequately paying off in an increased rate of newly approved drugs by the FDA. The post-genomic era has provided a wealth of novel approaches for generating large, high-dimensional genetic and transcriptomic data sets from large cohorts of preclinical species as well as normal and diseased individuals. This systems biology approach to understanding disease-related biology is revolutionizing our understanding of the cellular pathways and gene networks underlying the onset of disease, and the mechanisms of pharmacological treatments that ameliorate disease phenotypes. In this article, we review a number of approaches being used by pharmaceutical and biotechnology companies, e.g., high-throughput DNA genotyping, sequencing, and genome-wide gene expression profiling, to enable drug discovery and development through the identification of new drug targets and biomarkers of disease progression, drug pharmacodynamics, and predictive markers for selecting the patients most likely to respond to therapy.
    Current topics in microbiology and immunology 08/2012; 363. DOI:10.1007/82_2012_252 · 3.47 Impact Factor
  • Source
    [Show abstract] [Hide abstract]
    ABSTRACT: There is an urgent need for pre-clinical and clinical biomarkers predictive of vaccine immunogenicity, efficacy and safety to reduce the risks and costs associated with vaccine development. Results emerging from immunoprofiling studies in non-human primates and humans demonstrate clearly that (i) type and duration of immune memory are largely determined by the magnitude and complexity of the innate immune signals and (ii) genetic signatures highly predictive of B-cell and T-cell responses can be identified for specific vaccines. For vaccines with similar composition, e.g. live attenuated viral vaccines, these signatures share common patterns. Signatures predictive of vaccine efficacy have been identified in a few experimental challenge studies. This review aims to give an overview of the current literature on immunoprofiling studies in humans and also presents some of our own data on profiling of licensed and experimental vaccines in non-human primates.
    Microbial Biotechnology 11/2011; 5(2):177-87. DOI:10.1111/j.1751-7915.2011.00317.x · 3.21 Impact Factor
Show more